(FROM THE WALL STREET JOURNAL 3/23/15) 

Skadden Wins With Deal,

And Loses at Same Time

One way to ensure an M&A win: Get hired on both sides of the deal.

That's the position in which Skadden, Arps, Slate, Meagher & Flom LLP found itself recently.

The elite corporate law firm was in the unusual position of representing both Valeant Pharmaceuticals International Inc. and Endo International PLC in their dueling bids to buy Salix Pharmaceuticals Ltd.

Valeant, which Skadden advised on finance and antitrust matters, won out last Monday with a recut $11.1 billion cash deal.

Endo, for which Skadden served as lead M&A counsel, quickly bowed out, withdrawing the competing, cash-and-stock offer it had lobbed in earlier.

A Skadden spokeswoman declined to comment.

Law firms, sensitive about conflicts and wary of offending clients, rarely pitch work on multiple sides of the same deal.

But Skadden's relationships with both bidders go way back. The firm advised Valeant on its acquisitions of Medicis Pharmaceutical Corp. in 2012 and Bausch & Lomb in 2013, and on a high-profile takeover attempt of Allergan last year.

Skadden's ties to Endo go back nearly two decades, including advising private-equity shop Kelso & Co. in 1997 in a $277 million management buyout at what was then DuPont Merck Pharmaceutical Co.

-- Liz Hoffman

Law-School Applications

Head Even Lower in 2015

The latest numbers on law-school applications released by the Law School Admission Council are eye-opening.

As of March 13, 41,136 people have applied to go to an accredited U.S. law school this fall, according to LSAC, which administers the LSAT entrance exam.

By this time a year ago, the total number of applicants recorded had reached 43,156. Applications are down 6.7% from 2014.

-- Jacob Gershman

'Sniper' Case Focuses

On First Amendment

First Amendment advocates and major media companies are urging a federal appeals court to throw out a defamation judgment against the late "American Sniper" author Chris Kyle that entitled former Minnesota Gov. Jesse Ventura to more than $1 million of the royalties from the book.

The case is an appeal by Mr. Kyle's widow of last year's jury verdict in favor of Mr. Ventura, who sued the former Navy SEAL sharpshooter over his account of an alleged bar fight between the two men.

On top of a $500,000 damages award, a Minnesota jury awarded the former wrestler $1.35 million for unjust enrichment, draining some of the profit generated by Mr. Kyle's best-seller-turned blockbuster film.

Unless reversed, the $1.35 million award would set a troubling precedent that "cannot be reconciled with the First Amendment," wrote First Amendment litigator Floyd Abrams in a brief filed with the Eighth U.S. Circuit Court of Appeals on Wednesday.

About three dozen media companies and trade organizations joined the brief.

An attorney representing Mr. Ventura said the former governor's legal team would file a formal response with the court

-- Jacob Gershman

Access Investor Kit for Valeant Pharmaceuticals International, Inc.

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=CA91911K1021

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Valeant Pharma Charts.
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Valeant Pharma Charts.